3O: Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts
2025 · Journal of Thoracic Oncology · 5 citations
https://doi.org/10.1016/s1556-0864(25)00198-4
B
B-C. Goh
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
15
Papers
243
Citations
4
h-index
2
i10-index
B-C. Goh is an academic researcher from National University Cancer Institute, Singapore. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research. The author has an h-index of 4, co-authored 13 publications.
Papers by this author
works166P Integrative multi-omics refine molecular diagnostics in non-small cell lung cancer
2024 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2024.08.2171
LBA75 Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study
2025 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2025.09.089
25P Targeting STAT3-mediated liver pathogenesis through novel RNA therapeutics strategies
2025 · ESMO Open · 0 citations
https://doi.org/10.1016/j.esmoop.2025.104182
205eP Stool microbial signatures linked to immune checkpoint inhibitor response: A pan-tumour analysis in an Asian cohort
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.638
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat